For example, the HRD scores of patients with prostate cancer were significantly lower than those of patients with ovarian cancer, and the HRD scores of patients with prostate cancer and BRCA2 mutations were significantly higher than those of patients with ATM and CHEK2 mutations. Here, CHEK2 is linked to prostate carcinoma.